COST EFFECTIVENESS ANALYSIS OF EXEMESTANE VERSUS CAPECITABINE MONOTHERAPY FOR PATIENTS WITH HORMONE RECEPTOR–POSITIVE AND HER2-NEGATIVE, METASTATIC BREAST CANCER FROM NATIONAL CANCER INSTITUTE PRESPECTIVE IN EGYPT

Author(s)

Abdallah H1, Abourawash AS1, Elgazzar M2, Helal A2
1CAPA, Ministry of Health and Population, Cairo, Egypt, 2National Cancer Institute (NCI), Cairo University, Cairo, Egypt

OBJECTIVES:

Both hormonal therapy (HT) and maintenance Capecitabine mono therapy (MCT) have been shown to extend time to progression (TTP) in patients with metastatic breast cancer (MBC) after failure of taxanes and anthracycline-containing regimens. The main objective of this study is to evaluate over a 4- year period from National Cancer Institute the costs and outcomes associated with the use of Exemestane 25mg versus Capecitabine 400mg in patients with metastatic breast cancer.

METHODS:

A Markov model with three mutually exclusive health states (metastasis, progression and death) was developed. Transition probabilities used in the model were calculated based on time to progression and overall survival data which derived from previously published clinical trial. Utility data was derived from previously published sources. Direct medical costs were collected from The National Cancer Institute. Costs and effects were discounted at 3.5% annually. Deterministic sensitivity analysis was performed.

RESULTS:

The total QALYs of the Exemestane group were estimated to be 167.3 compared with 129.5 for the Capecitabine group, with a net difference of 37.7 QALYs. The total costs for the Exemestane group and Capecitabine group were 1,699,087 EGP and 2,389,345 EGP respectively, with a net difference of 690258 EGP. These results showed that Exemestane provide better QALYS at lower costs compared to Capecitabine. Deterministic sensitivity analysis showed that time to progression in Exemestane group has the largest impact on the results.

CONCLUSIONS:

Exemestane 25 mg is cost saving compared to capecitabine 400 mg in patients with metastatic breast cancer and should be recommended in National Cancer Institute tender list.

Conference/Value in Health Info

2017-11, ISPOR Europe 2017, Glasgow, Scotland

Value in Health, Vol. 20, No. 9 (October 2017)

Code

PCN124

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×